JNJ

The company traces to a speech. In 1885 the British surgeon Joseph Lister was arguing that invisible airborne germs caused post-surgical infection and that antiseptic technique could prevent it. Robert Wood Johnson heard the case, partnered with his brothers James Wood Johnson and Edward Mead Johnson, and in 1886 began producing ready-to-use sterile surgical dressings from a small factory in New Brunswick. The premise was simple and, at the time, contrarian. If wound dressings arrived already sterile and individually wrapped, surgeons would no longer have to improvise from whatever cloth was nearby, and infection rates would fall. That single idea, mass-produced sterility, seeded a healthcare conglomerate. Over the following century Johnson & Johnson layered consumer staples, pharmaceuticals, and surgical equipment on top of the original dressings business, expanding largely through acquisition and decentralization. For decades the company was run as a loose federation of operating companies, each with significant autonomy, an unusual structure that the firm credited for its adaptability and that critics blamed for inconsistent oversight.

The structure that matters now is far simpler. As of 2025 Johnson & Johnson reports through two segments. Innovative Medicine is the pharmaceutical arm and the larger of the two, contributing roughly two thirds of company sales. It develops and sells branded prescription drugs across oncology, immunology, neuroscience, cardiovascular and pulmonary disease, and other areas. MedTech is the medical device arm and makes up the remainder. It spans cardiovascular intervention, surgery, orthopaedics, and vision care, selling hardware and consumables to hospitals and clinicians rather than medicines to patients. The two segments share little operationally. A drug discovery organization and a device manufacturing organization run on different timelines, different regulatory pathways, and different sales motions. What they share is the corporate balance sheet, the brand, and a diversification logic that has defined the company for generations.

That diversification is the heart of the investment case and the source of the company's durability. Healthcare demand is relatively insensitive to the economic cycle, since people need treatment regardless of recessions, and Johnson & Johnson spreads its exposure across dozens of disease areas and product lines so that no single failure sinks the whole. A patent expiry on one drug, a recall on one device, or a soft quarter in one therapeutic area can be absorbed by strength elsewhere. This breadth, combined with enormous scale in manufacturing, distribution, and regulatory affairs, is the moat. Bringing a new drug or implantable device through trials and approvals costs hundreds of millions to billions of dollars and takes many years, a barrier that protects incumbents with deep pipelines and punishes thinly capitalized challengers. Johnson & Johnson reinvests heavily into that pipeline, spending tens of billions of dollars a year combined on research and development and acquisitions, which is how a company this old keeps replacing the revenue that patents inevitably erase.

The pharmaceutical portfolio as of the mid 2020s leans on a handful of large franchises. In oncology, the multiple myeloma antibody Darzalex has grown into the company's single biggest product, and the cell therapy Carvykti reached blockbuster scale, while Rybrevant and Lazcluze address lung cancer and Erleada treats prostate cancer. In immunology, Tremfya has become a major growth driver in psoriasis and inflammatory bowel disease, helping offset the decline of the company's former immunology anchor. In neuroscience, the depression treatment Spravato has scaled quickly, and the 2025 acquisition of Intra-Cellular Therapies for roughly fourteen and a half billion dollars added Caplyta, a schizophrenia and bipolar depression drug the company expects to become another large seller. The MedTech side has been reshaped by two large heart-device acquisitions, Abiomed and Shockwave Medical, bought for a combined sum near thirty billion dollars, which turned cardiovascular intervention into one of the device segment's fastest growing areas alongside its established electrophysiology business.

Competition is intense and specific to each franchise rather than companywide. In pharmaceuticals Johnson & Johnson contends with the other large drugmakers, including Pfizer, Merck, AbbVie, Bristol Myers Squibb, Roche, Novartis, and Eli Lilly, each fielding its own oncology and immunology pipelines. The sharpest near-term pressure comes from biosimilars and generics rather than from any one rival. Stelara, long one of the company's most important immunology drugs, lost United States patent protection at the start of 2025, and a wave of biosimilar competitors began taking share, the kind of patent cliff that periodically forces the company to prove its pipeline can grow faster than its legacy products fade. In MedTech the competitors are device specialists such as Medtronic, Stryker, Boston Scientific, Abbott, and Intuitive Surgical, each strong in particular niches. Johnson & Johnson tends to win on breadth and on the strength of individual platforms rather than by dominating any single device category.

Leadership sits with Joaquin Duato, who became chief executive in January 2022 and added the chairman title in January 2023. Duato is a long-tenured insider who spent decades inside the company's pharmaceutical business before taking the top job, and his tenure has been defined by simplification. He oversaw the separation of the consumer health unit, concentrated the company on medicines and devices, and steered the largest acquisitions in its recent history. The strategy has been consistent. Shed lower-growth businesses, push capital toward higher-growth therapeutic and device areas, and let scale and pipeline do the compounding. The company also operates under a written statement of values known as the Credo, first drafted in 1943, which ranks responsibilities to patients, employees, communities, and shareholders in that order. The document is invoked frequently in corporate communications and is treated internally as a governing philosophy rather than a marketing slogan, though outside observers judge the company on outcomes rather than on the text.

The forward strategy continues that pruning. In late 2025 Johnson & Johnson announced plans to separate its orthopaedics business, one of the larger device franchises, over a roughly eighteen to twenty-four month period, leaving the company anchored on six priority areas across its two segments, namely oncology, immunology, and neuroscience in Innovative Medicine, and cardiovascular, surgery, and vision in MedTech. The logic mirrors the Kenvue spinoff. Concentrate management attention and capital on the fastest-growing, highest-margin parts of the portfolio and let slower or structurally different units stand on their own. The bet is that a more focused Johnson & Johnson can grow faster than the sprawling conglomerate of the past, even as it gives up the revenue and the diversification that the divested units provided.

The dominant risk is not commercial but legal, and it is unusually large. For years the company has faced tens of thousands of lawsuits alleging that its talc-based baby powder, long since pulled from the market, contained asbestos and caused ovarian cancer and mesothelioma. Johnson & Johnson maintains that its talc is safe and that the science does not support the claims, and it has tried three times to route the liability into a bankruptcy of a small subsidiary in order to settle the cases collectively, a maneuver sometimes called the Texas two-step. Courts rejected all three attempts, most recently in March 2025, when a Texas bankruptcy court declined to confirm the plan and the company reversed roughly seven billion dollars of reserves it had set aside. Johnson & Johnson then said it would return to the ordinary tort system and litigate the claims case by case rather than settle. The financial exposure is genuinely uncertain. Individual jury verdicts have at times reached into the billions before appeals, and the ultimate cost depends on outcomes that no one can confidently forecast. Beyond talc, the company carries the ordinary risks of its industry, including pipeline failures in clinical trials, pricing pressure from governments and insurers, regulatory scrutiny of drug prices in the United States, and the steady erosion of patents that requires constant replacement.

The way to weigh Johnson & Johnson is as a trade between stability and ceiling. The company has assembled a genuinely diversified healthcare franchise with a fortress balance sheet, a record of raising its dividend through more than six decades of recessions and crises, and a pipeline deep enough to have survived multiple patent cliffs before this one. That same breadth and maturity also cap how fast it can grow, since a company of this size cannot move like a single-drug biotech, and the simplification strategy trades diversification for focus in a wager that concentration will lift the growth rate. Layered on top is the talc litigation, an open-ended legal liability that resists clean estimation and that the company has chosen to fight rather than settle. The central question for an investor is whether the steadiness of a diversified healthcare leader, now sharpened into two focused segments, is worth holding through a litigation overhang whose final cost remains unknown, and whether the bet on focus delivers the faster growth that the breakup thesis promises.